

Lucy E Vivash

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2960912/publications.pdf>

Version: 2024-02-01

35
papers

1,359
citations

516710

16
h-index

395702

33
g-index

42
all docs

42
docs citations

42
times ranked

2672
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. <i>Brain</i> , 2018, 141, 391-408.	7.6	352
2	Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 165-168.	5.0	145
3	White matter abnormalities across different epilepsy syndromes in adults: an ENIGMA-Epilepsy study. <i>Brain</i> , 2020, 143, 2454-2473.	7.6	123
4	Network-based atrophy modeling in the common epilepsies: A worldwide ENIGMA study. <i>Science Advances</i> , 2020, 6, .	10.3	97
5	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. <i>Neurotherapeutics</i> , 2019, 16, 192-202.	4.4	69
6	Assessment of the DTI-ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia. <i>Journal of Neuroimaging</i> , 2021, 31, 569-578.	2.0	68
7	¹⁸ F-Flumazenil: A β -Aminobutyric Acid A-Specific PET Radiotracer for the Localization of Drug-Resistant Temporal Lobe Epilepsy. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1270-1277.	5.0	61
8	A Phase IIa Randomized Control Trial of β -VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 223-232.	2.6	53
9	The ENIGMA-Epilepsy working group: Mapping disease from large data sets. <i>Human Brain Mapping</i> , 2022, 43, 113-128.	3.6	47
10	Atlas of lesion locations and postsurgical seizure freedom in focal cortical dysplasia: A MELD study. <i>Epilepsia</i> , 2022, 63, 61-74.	5.1	36
11	Metabolic patterns and seizure outcomes following anterior temporal lobectomy. <i>Annals of Neurology</i> , 2019, 85, 241-250.	5.3	25
12	Artificial intelligence for classification of temporal lobe epilepsy with ROI-level MRI data: A worldwide ENIGMA-Epilepsy study. <i>NeuroImage: Clinical</i> , 2021, 31, 102765.	2.7	25
13	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. <i>Alzheimer's and Dementia</i> , 2022, 18, 2218-2233.	0.8	24
14	In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 958-965.	6.4	22
15	In Vivo Measurement of Hippocampal GABA/cBZR Density with [18F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy. <i>PLoS ONE</i> , 2014, 9, e86722.	2.5	22
16	A systems-level analysis highlights microglial activation as a modifying factor in common epilepsies. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	22
17	Changes in hippocampal GABA/cBZR density during limbic epileptogenesis: Relationship to cell loss and mossy fibre sprouting. <i>Neurobiology of Disease</i> , 2011, 41, 227-236.	4.4	19
18	Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [¹⁸ F]-FEMPA PET Study. <i>Movement Disorders</i> , 2022, 37, 218-224.	3.9	18

#	ARTICLE	IF	CITATIONS
19	Topographic divergence of atypical cortical asymmetry and atrophy patterns in temporal lobe epilepsy. <i>Brain</i> , 2022, 145, 1285-1298.	7.6	18
20	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. <i>BMJ Open</i> , 2020, 10, e040100.	1.9	11
21	Event-based modeling in temporal lobe epilepsy demonstrates progressive atrophy from cross-sectional data. <i>Epilepsia</i> , 2022, 63, 2081-2095.	5.1	11
22	Machine learning approaches for imaging-based prognostication of the outcome of surgery for mesial temporal lobe epilepsy. <i>Epilepsia</i> , 2022, 63, 1081-1092.	5.1	10
23	Semi-automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1631-1638.	3.4	9
24	Low prevalence of amyloid and tau pathology in drug-resistant temporal lobe epilepsy. <i>Epilepsia</i> , 2021, 62, 3058-3067.	5.1	8
25	Sodium selenate as a disease-modifying treatment for mild-to-moderate Alzheimer's disease: an open-label extension study. <i>BMJ Neurology Open</i> , 2021, 3, e000223.	1.6	7
26	A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12299.	3.7	7
27	The effect of injection time on rates of epileptogenic zone localization using SISCOM and STATISCOM. <i>Epilepsy and Behavior</i> , 2021, 118, 107945.	1.7	6
28	Development of [¹⁸ F]MIPS15692, a radiotracer with in vitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113822.	5.5	5
29	Ictal cerebral blood flow in psychogenic non-epileptic seizures: a preliminary SPECT study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2018-320173.	1.9	4
30	Cognitive profiles in patients with epileptic and nonepileptic seizures evaluated using a brief cognitive assessment tool. <i>Epilepsy and Behavior</i> , 2021, 115, 107643.	1.7	4
31	Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2021, 11, e055019.	1.9	4
32	Longitudinal changes of focal cortical glucose hypometabolism in adults with chronic drug resistant temporal lobe epilepsy. <i>Brain Imaging and Behavior</i> , 2021, 15, 2795-2803.	2.1	2
33	A phase 1B open-labelled study of sodium selenate as a disease modifying treatment for possible behavioural variant frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e039192.	0.8	1
34	Neurofilament light chain in psychiatric and neurodegenerative disorders: A reactive protein for the brain?. <i>Alzheimer's and Dementia</i> , 2020, 16, e041347.	0.8	1
35	A phase 1b open label study of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0